Comparative tolerability and efficacy of treatments for impotence

Drug Safety

Volumn 20, Issue 2, 1999, Pages 133-146

  Meinhardt, Willem ^a   Kropman, René F ^b   Vermeij, Pieter ^c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARGININE; CLOMIPRAMINE; FLUOXETINE; PAPAVERINE; PAROXETINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; TRAZODONE; YOHIMBINE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROSIS; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PENIS DISEASE; PREMATURE EJACULATION; PRIAPISM; PRIORITY JOURNAL; REVIEW;

APHRODISIACS; EJACULATION; HUMANS; IMPOTENCE; LIBIDO; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 0032991295     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920020-00004     Document Type: Review

References (114)

1. Edwards IR, Wilholm BE, Martinez C. Concepts in risk-benefit assessment, a simple merit analysis of a medicine? Drug Safely 1996; 15: 1-7
2. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-235
3. Finberg JPM, Levy S, Vardi Y. Inhibition of nerve simulation-induced vasodilatation in corpora cavernosa of the pithed rat by blockade of nitric oxide synthase. Br J Pharmacol 1993; 108: 1038-43
4. Trigo-Rocha F, Hsu GL, Donatucci CF, et al. The role of cyclic adenosine monophospate, cyclic guanosine monophosphate, endothelium and nonadrenergic neurotransmission in canine penile erection. J Urol 1993; 149: 872-7
5. Shafik A. Response of the urethral and intracorporeal pressures to cavernosus muscle stimulation: role of the muscles in erection and ejaculation. Urology 1995; 46: 85-88
6. Christ GJ, Lerner SE, Kim C, et al. Endothelin-I as a putative modulator of erectile dysfunction: I: characteristics of contraction of isolated corporal tissue strips. J Urol 1995; 153: 1998-2003
7. Ferro CJ, Webb DL. Endothelial dysfunction and hypertension. Drugs 1997; 53 Suppl. 1: 30-1
8. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4
9. Burnett AL, Lowenstein CJ, Bredt DS, et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-3
10. Meinhardt W. Treatment of erectile dysfunction, the conservative urologic options [thesis]. Leiden: Univ. of Leiden, 1997
11. Goldberg MR, Robertson D. Yohimbine: a pharmacological probe of the a2-adrenoceptor. Pharmacol Rev 1983; 35: 143-80
12. Andersson KE, Holmquist F, Wagner G. Pharmacology of drugs used for treatment of erectile dysfunction and priapism. Int J Impot Res 1991; 3: 155-72
13. Costa P, Sarrazin B, Bressolle F, et al. Efficiency and side-effects of intra cavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. J Urol 1993; 149: 301-5
14. Costa P, Bressolle F, Sarrazin B, et al. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and intracavernous administration. J Pharm Sci 1993; 82: 729-33
15. Costa P, Bressolle F, Mottet N, et al. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous infusion and intracavernous administration with and without a penile tourniquet. Ther Drug Monit 1996; 18: 135-44
16. Hedlund H, Andersson K-E. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985; 134: 1245
17. Jünemann K-P, Lue TF, Fournier jr GR, Tanagho EA. Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol 1986; 136: 158-61
18. Montorsi F, Guazzoni G, Rigatti P, et al. Pharmacological management of erectile dysfunction. Drugs 1995; 50: 465-79
19. Truss MC, Becker AJ, Djamilian MH, et al. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-I) in the diagnosis and treatment of erectile dysfunction. Urology 1994; 44: 553-6
20. Jeremy JY, Ballard SA, Naylor AM, et al. Effects of sildafenil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958-63
21. Thompson WJ. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 1991; 51: 13-33
22. Gartrell N. Increased libido in women receiving trazodone. Am J Psychiatry 1986; 143: 781-2
23. Sullivan G. Increased libido in Three men treated with trazodone. J Clin Psychiatry 1988; 49: 202-3
24. Abber JC, Lue TF, Jünemann KP, et al. Priapism induced by chlorpromazine and trazodone: mechanism of action. J Urol 1987; 137: 1039-42
25. Saenz de Tejada I, Gatesby Wae J, Blanco R, et al. Patho-physiology of prolonged penile erection associated with trazodone use. J Urol 1991; 145: 60-4
26. Meinhardt W, Schmitz PIM, Kropman RF, et al. Trazodone, a double blind trial for treatment of erectile dysfunction. J Impot Res 1997; 9: 163-5
27. Waldinger MD. Use of psychoactive agents in the treatment of sexual dysfunction. Drug Ther 1996; 6: 204-16
28. Rosen RC. Prosexual drugs: empirical status of the 'new aphrodisiacs'. Arch Sex Behavior 1993; 22: 521-43
29. Haensel SM, Mos J, Van der Schoot, et al. Testosterone is required for the stimulatory effects of 8-OH-DPAT on sexual behavior in castrated male rats. Eur J Pharmacol 1993; 233: 187-92
30. Heaton JPW, Varrin SJ. Effects of castration and exogenous testosterone supplementation in an animal model of penile erection. J Urol 1994; 151: 797-800
31. Gooren LJG. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212-5
32. Danjou P, Alexandre L, Warot D, et al. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988; 26: 733-9
33. Clark JT, Smith ER, Davidson JM. Enhancement of sexual motivation in male rats by yohimbine. Science 1984; 225: 847-9
34. Dourish CT, Cooper SJ, Philips SR. Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat. Psychopharmacology (Berl) 1985; 86: 175-81
35. Morales A, Condra MS, Owen JE, et al. Oral and transcutaneous pharmacologic agents in the treatment of impotence. Urol Clin North Am 1988; 15: 87-93
36. Susset JG. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989; 141: 1360-3
37. Reid K, Surridge DHC, Moralis A, et al. Double-blind trial of Yohimbine in treatment of psychogenic impotence. Lancet 1987; II: 421-3
38. Morales A, Condra M, Owen JA, et al. Is yohimbine effective in the treatment of organic impotence? J Urol 1987; 137: 1168-72
39. Kunelius P, Häkkinen J, Likkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence?: a prospective, randomised, controlled double-blind crossover study. Urology 1997; 49: 441-4
40. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomised clinical trials. J Urol 1998; 159: 433-6
41. Erectile Dysfunction Clinical Guidelines Panel. Report on a treatment of organic erectile dysfunction. Baltimore (MD): American Urologic Association, 1996
42. Montorsi F, Barbieri L, Strumbi LF, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomised double blind, placebo controlled study. Urology 1994; 44: 732-6
43. Becker AJ, Stief CG, Machtens S, et al. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998; 159: 1214-7
44. Heaton JPW, Morales A, Adames MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200-6
45. Boolell M, Gepi-Attee S, Gingell JC, et al. Sildenafil, A novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-61
46. Price D, Gingell JC, Gepi-Attee S, et al. Sildenafil, a novel orally efficacious treatment for male erectile dysfunction in patients with diabetes [abstract]. Diabetes 1996; 45 Suppl. 2: 6A
47. Derry F, Gardner BP, Glass C, et al. Sildenafil (Viagra®): a double-blind, placebo-controlled, single dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury [abstract]. J Urol 1997; 157: 181A
48. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (Viagra®) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10; 69-74
49. Lue TF, Group SS. A study of sildenafil (Viagra): a new oral agent for the treatment of male erectile dysfunction [abstract]. J Urol 1997; 157: 181A
50. Feenstra J, van Drie-Pierik RJHM, Lacle CF, et al. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 957-8
51. Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 1994; 6: 33-7
52. Georgitis WJ, Merenich JA. Trial of pentoxifylline for diabetic impotence. Diabetes Care 1985; 18: 345-52
53. Knoll LD, Benson jr RC, Bilhartz DL, et al. A randomized cross-over study using yohimbine and isoxsupirine versus pentoxifylline in the management of vasculogenic impotence. J Urol 1996; 155: 144-6
54. Guay AT, Bansal S, Heatly GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995; 80: 3546-52
55. Gilja I, Parazajder J, Radej M, et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994; 25: 226-8
56. Murphy JB, Lipshultz LI. Abnormalities of ejaculation. Urol Clin N Am 1987; 14: 583-96
57. Salkin P. Management of impotence and infertility. In: White-head ED, Nagler HM, editors. Philadelphia (PA): Lippincott Company, 1994; 197
58. Goodman RE. An assessment of clomipramine (Anafranil®) in the treatment of premature ejaculation. J Int Med Res 1980; 8 Suppl. 3: 53
59. Haensel SM, Rowland DI, Kallan KTHK, et al. Clomipramine an sexual function in men with premature ejaculation and controls. J Urol 1996; 156: 1310-6
60. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind randomized, placebo-controlled study. Am J Psychiatry 1994; 151: 1377
61. Foster P, King J. Fluoxetine for premature ejaculation. Am J Psychiatry 1994; 151: 1523
62. Kara H, Aydin S, Agarcün MY, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo-controlled study. J Urol 1996; 156: 1631-2
63. Waldinger MD, Hengeveld MW, Zwinderman AH. Effects of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharmacol 1998; 18: 274-81
64. Waldinger MD, Hengeveld MW, Zwinderman AH. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br J Urol 1997; 79: 592-5
65. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998; 159: 425-7
66. Meinhardt W, de la Fuente RB, Lycklama à Nijeholt AAB, et al. Prostaglandin E-1 with phentolamine for the treatment of erectile dysfunction, Int J Impot Res 1996; 8: 5-8
67. Ishii N, Watanabe H, Irisawa C, et al. Intracavernous injection of prostaglandine E-1 for the treatment of erectile impotence. J Urol 1989; 141: 323-5
68. Stackl W, Hasun R, Marlberger M. Intracavernous injection of prostaglandine E-1 in impotent men. J Urol 1988; 140: 66-8
69. Godschalk M, Gheorghiu D, Chen J, et al. Long-term efficacy of a new formulation of prostaglandin E-1 as treatment for erectile failure. J Urol 1996; 155: 915-17
70. Schramek P, Waldhauser M. Dose-dependent effect and side-effect of prostaglandine E-1 in erectile dysfunction. Br J Clin Pharmacol 1989; 28: 567-71
71. Vanderscheuren D, Heyrman RM, Keogh EJ, et al. A study in patients with erectile dysfunction comparing different formulations of prostaglandin El. J Urol 1995; 154: 1744-7
72. Porst H. The rationale for prostaglandine El in erectile failure; a survey of worldwide experience. J Urol 1996; 155: 802-15
73. Padma-Nathan H, Hellstrom WJG, Kaiser FE. Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl J Med 1997; 336: 1-7
74. Phentolamine. In: McEnvoy GK, editor. Drug information. Bethesda (MD): American Hospital Formulary Service, 1997; 1010
75. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 39-41
76. Jünemann KP, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989; 1: 71-93
77. Keogh EJ, Watters GR, Earle CM, et al. Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double blind, cross-over trial. J Urol 1989; 142: 726-8
78. Porst H. Penile fibrosis in intracavernosal prostaglandin El injection therapy for erectile dysfunction - comment. Int J Impot Res 1997; 9: 229-30
79. Linet OI, Ogring FG. Penile fibrosis during 10 months of intracavernosal therapy with alprostadil (Caverject™) [abstract]. Int J Impot Res 1996; 8 Suppl. 143; D85
80. Liner OI, Ogring FG, Group AS. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New Engl J Med 1996; 334: 873-7
81. Seidmon EJ, Jr Samara AM. The pH analysis of papaverine-phentolamine and prostaglandine El for pharmacologic erection. J Urol 1989; 141: 1458-9
82. Meinhardt W, Lycklama à Nijeholt AAB, Kropman RF, et al. Comparison of a mixture of papaverine, phentolamine and prostaglandine E-1 with other cavernous injections. Eur Urol 1994; 26: 319-21
83. Godschalk M, Gheorghiu D, Katz PG, et al. Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandine El. J Urol 1996; 156: 999-1000
84. Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction [abstract]. J Urol 1993; 149 Suppl.: 319A
85. Schoumann M, Lacroix P, Amer M. Suppression of prostaglandine El-induced pain by dilution of the drug with lidocaine before intracavernous injection [letter to the editor]. J Urol 1992; 148: 1266
86. Schramek P, Plas EG, Hübner WA, et al. Intracavernous injection of prostaglandine El plus procaine in the treatment of erectile dysfunction. J Urol 1994; 152: 1108-10
87. Gheorghiu D, Godschalk M, Gheorghiu S, et al. Slow injection of prostaglandine El decreases associated penile pain. Urology 1996; 47: 903-4
88. Moreland RB, Traish A, McMillin MA, et al. PGEI suppresses the induction of collagen synthesis by transforming growth factor-BI in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-34
89. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after longterm intracavernous injection for impotence. Urology 1994; 43: 844-8
90. Sundaram CP, Thomas W, Pryor LE, el al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932-5
91. Lakin MM, Montague DK, Vandenbrug Medendorp S. et al. Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138-41
92. Levine SB, Althof SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54-7
93. Bénard F, Lue TF. Self-administration in the pharmacological treatment of impotence. Drugs 1990; 39: 394-8
94. Sarosdy MF, Hudnall CH, Erickson DR, et al. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin El in the treatment of impotence. J Urol 1989; 141: 551-3
95. Earle CM, Keogh EJ, Wisniewski ZS, et al. Proslaglandine El therapy for impotence, comparison with papaverine. J Urol 1990; 143: 57-9
96. Lee LM, Stevenson RWD, Szasz G. Prostaglandine El versus phentolamine/papaverine for treatment of erectile impotence: a double-blind comparison. J Urol 1989; 141: 549-53
97. Meyer JM, Oosterlinck W. Influence of the method of intracavernous injection on penile rigidity: a possible pharmacokinetic explanation. Urology 1997; 49: 248-52
98. Bennett AH, Carpenter AJ, Barda JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 1564-5
99. Montorsi F, Guazonni G, Bergamaschi F, et al. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol 1993; 149: 1291-5
100. Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-years experience with 615 cases. J Urol 1991; 145: 287-93
101. McMahon CG. A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandine PGEl and a combination of all three in the management of impotence. Int J Impot Res 1991; 3: 113-21
102. Dinsmore WW, Alerdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998; 81: 437-40
103. Djamilian M, Stief CG, Kuczyk M, et al. Follow-up results of a combination of calcitonin gene-related peptide and prostaglandine El in the treatment of erectile dysfunction. J Urol 1993; 149: 1296-8
104. Mulhall J, Daller M, Traish A, et al. Intracavernosal forskolin: role in the management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol 1997; 158: 1752-8
105. Buvat J, Costa P, Morlier D, et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998; 159: 116-9
106. Van Heyden B, Brock GB, Martinez-Pineiro L, et al. Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long term use. Eur Urol 1996; 30: 502-5
107. Vardi Y, Saenz de Tejada I, Functional and radiologic evidence of vascular communication between the sponsiosal and cavernosal compartments of the penis. Urology 1997; 49: 749-52
108. Padma-Nathan H, Tam PY, Place VA. Improved erectile response to transurethral alprostadil by use of a novel, adjustable penile band [abstract]. J Urol 1997; 157 Suppl.: 181A
109. Meyhoff HH, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitroglycerin. Br J Urol 1992; 69: 88-90
110. Mudd JW. Impotence responsive to glyceryl trinitrate. Am J Psychiatry 1977; 134: 922-5
111. Cavallini G. Minoxidil versus nitroglycerin: prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991; 146: 50-3
112. Hellstrom WJG, Bennett AH, Gesundheit N, et al. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 1996; 48: 851-6
113. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous Alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impotence Res 1997; 9: 187-92
114. Armstrong DKB, Convery AG, Dinsmore WW. Reasons for patient drop-out from an intracavernous autoinjection program for erectile dysfunction. Br J Urol 1994; 74: 99-10